The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-06 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Society and culture == The scalp plays an important role in the aesthetics of the face. Androgenic alopecia, or male pattern hair loss, is a common cause of concern to men. It may be treated with varying rates success by medication (e.g. finasteride, minoxidil) or hair transplantation. If the scalp is heavy and loose, a common change with ageing, the forehead may be low, heavy and deeply lined. The brow lift procedure aims to address these concerns. Scalping is the act of removing a human scalp, usually with hair, as a trophy. Often associated with the history of North America, scalping developed independently on multiple continents and dates back to antiquity.
=== Biochemical synthesis === Glycocyamine is formed in the mammalian organism primarily in the kidneys by transferring the guanidine group of L-arginine by the enzyme L-Arg:Gly-amidinotransferase (AGAT) to the amino acid glycine. From L-arginine, ornithine is thus produced, which is metabolized in the urea cycle by carbamoylation to citrulline.
Subsequent authors have debated who the "primary author" really was. In his posthumously published 1981 book The Anglo-American Establishment, Georgetown University history professor Carroll Quigley explained his view that Lord Milner was the primary author of the declaration, and more recently, William D. Rubinstein, Professor of Modern History at Aberystwyth University, Wales, proposed Amery instead. Huneidi wrote that Ormsby-Gore, in a report he prepared for Shuckburgh, claimed authorship, together with Amery, of the final draft form.
Sources: en.wikipedia.org
== Theoretical Analysis of an Ideal Penning Trap == The motion of a single charged particle in an ideal Penning trap (with perfect alignment of its magnetic field to the quadrupole potential) is an exactly solvable system in both classical and quantum mechanics. The particle's motion along the trap's axis is simple harmonic motion, and the motion in the trap's xy-plane is a perturbation of cyclotron motion that reduces to cyclotron motion exactly in the zero-electric-field limit.
== History == LG CNS was founded in 1987 as System Technology Management (STM), a 50:50 joint venture between LG and Electronic Data Systems. In 1995, the company was renamed LG-EDS System as part of LG Group's corporate identity integration project. After LG acquired all of EDS's shares, the company changed its name to LG CNS in January 2002. In 2019, LG sold a 35% stake in LG CNS to Macquarie Group for 1 trillion won (US$865 million). This sale occurred amid growing criticism of South Korea's chaebols for allegedly benefiting founding families by over-relying on outsourcing contracts and directing work to subsidiaries and affiliates. Macquarie acquired the stake in LG CNS with the condition that LG would list the company by April 2025. As a result, LG CNS debuted on the market in February 2025. On January 28, 2026, Macquarie divested its remaining 8.3% stake in the company through a block deal.
India is a federal union comprising 28 states and 8 union territories. All states, as well as the union territories of Jammu and Kashmir, Puducherry and the National Capital Territory of Delhi, have elected legislatures and governments following the Westminster system. The remaining five union territories are directly ruled by the central government through appointed administrators. In 1956, under the States Reorganisation Act, states were reorganised on a linguistic basis. Over a quarter of a million local government bodies operate at the city, town, district, block, and village levels.
== Honors and awards == Independent Scientist Research (K02) Award, National Institute of Mental Health, 2002–2007. Fellow, Association for Psychological Science, 2003. Fellow, Society for Personality and Social Psychology, 2005. Fellow, American Psychological Association, 2005. Career Trajectory Award, Society of Experimental Social Psychology, 2006. Cattell Fund Fellowship, 2007–2008. NIH Director's Pioneer Award, 2007–2012, to study how the brain creates emotion. Kavli Fellow, National Academy of Sciences, 2008. Elected Fellow, American Association for the Advancement of Science, 2008. Arts in Academics award, University of Waterloo, 2010. Excellence in Research and Creative Activity Award, Northeastern University, 2012. Elected Fellow, Royal Society of Canada, 2012. Award for Distinguished Service in Psychological Science, American Psychological Association, 2013. Elected Fellow, Society of Experimental Psychologists, 2013. Diener Award in Social Psychology, Society for Personality and Social Psychology, 2014. Heritage Wall of Fame, Foundation for Personality and Social Psychology, 2016. Mentor Award for Lifetime Achievement, Association for Psychological Science, 2018. Elected Fellow, American Academy of Arts and Sciences, 2018. President, Association for Psychological Science, 2019–2020. Guggenheim Fellowship in neuroscience, 2019. John P. McGovern Award in the Behavioral Sciences, American Association for the Advancement of Science, 2020. APA Award for Distinguished Scientific Contributions, American Psychological Association, 2021.
Sources: en.wikipedia.org
== Interactions of the platelet surface glycoproteins == The binding of von Willebrand factor (vWF) results in conformational changes within the GPIb-V-IX complex. In consequence, this complex activates GPIIb / IIIa membrane glycoproteins, allowing them to bind fibrinogen. Fibrinogen molecules then interconnect the platelets, serving as the basis for platelet aggregation. In the absence of fibrinogen, the platelets are joined by vWF due to its ability to bind the activated GPIIb / IIIa complex.
Thin basement membrane disease is an autosomal dominant inherited disease characterized by thin glomerular basement membranes on electron microscopy. It is a benign condition that causes persistent microscopic hematuria. This also may cause proteinuria which is usually mild and overall prognosis is excellent.
Electron capture is the primary decay mode for isotopes with a relative superabundance of protons in the nucleus, but with insufficient energy difference between the isotope and its prospective daughter (the isobar with one less positive charge) for the nuclide to decay by emitting a positron. Electron capture is always an alternative decay mode for radioactive isotopes that do have sufficient energy to decay by positron emission. Electron capture is sometimes included as a type of beta decay, because the basic nuclear process, mediated by the weak force, is the same. In nuclear physics, beta decay is a type of radioactive decay in which a beta ray (fast energetic electron or positron) and a neutrino are emitted from an atomic nucleus. Electron capture is sometimes called inverse beta decay, though this term usually refers to the interaction of an electron antineutrino with a proton. If the energy difference between the parent atom and the daughter atom is less than 1.022 MeV, positron emission is forbidden as not enough decay energy is available to allow it, and thus electron capture is the sole decay mode. For example, rubidium-83 (37 protons, 46 neutrons) will decay to krypton-83 (36 protons, 47 neutrons) solely by electron capture (the energy difference, or decay energy, is about 0.9 MeV).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.